. 2022 Oct 18;50(10):03000605221129154. doi: 10.1177/03000605221129154

Table 6.

Multivariate analysis of treatment-related risk factors for carbapenem-resistant Enterobacteriaceae in patients with or without concomitant SARS-CoV-2 (COVID-19) that were included in a retrospective case–control study that aimed to identify the strains of carbapenem-resistant Enterobacteriaceae and the risk factors associated with acquiring these infections.

Risk factors	Statistical analysis^a	Odds ratio	95% confidence interval
Risk factors	Statistical analysis^a	Odds ratio	Lower	Upper
Reserve antibiotics	NS	0.54	0.11	2.56
Carbapenem treatment	P = 0.026	5.09	1.21	21.27
Quinolone treatment	NS	5.67	1.00	35.32
Linezolid treatment	NS	1.79	0.15	21.41
Corticosteroid treatment	P = 0.012	7.06	1.53	32.39

^aBinary logistic regression analysis; NS, no significant association (P > 0.05).